arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Drugs Made In America Acquisition II Corp.

DMII

$10.11 0.00 (0.00%) at close

7 Visible periods

14 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Drugs Made In America Acquisition II Corp. shows mixed fundamentals. Consider comparing against peers in the Financials sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 0.6% ↘

FCF / Share —

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.03

info Valuation on last close. End-of-day price, Jul 31, 2026.

7-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$4.34M

— +0.2% —

Health Breakdown

Returns

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Net Income Growth YoY (%)	N/M	—	-42.3% Weak Weak Year-over-year change in net income	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
FCF / Net Income (x)	-0.02x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.07x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.17x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	3.72x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Return on Invested Capital (%)	0.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	1.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	0.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	26.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	492.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-0.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-0.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-24.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-303%)	-24.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-303%)	0.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-97%)	—	33.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+181%)	—	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Debt to Equity (x)	-0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-102%)	—	—	—	—	—	—
Net Debt (USD)	$102.28K	$-223.00	—	—	—	—	—
Debt / EBITDA (x)	-3.41x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—

📊 What does each share earn? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Book Value per Share (USD)	$-1.30	$-1.30	$-1.11	—	—	$-0.01	—
Tangible Book Value per Share (USD)	$-1.30	$-1.30	$-1.11	—	—	$-0.01	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Working Capital (USD)	$-314.52K	$-274.83K	$219.01K	—	—	$-195.17K	—
Total Equity (USD)	$-17.81M	$-17.77M	$-17.28M	$-214.12K	$-176.05K	$-116.72K	$-6.68K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗
Net Income, GAAP (USD)	$4.34M	$4.33M	$-59.33K	—	$-59.33K	—	$-41.68K
Operating Cash Flow (USD)	$-102.50K	$-314.86K	—	—	$-10.04K	—	$-155.06K

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 2 years · 7 quarters

Drugs Made In America Acquisition II Corp.

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare DMII with peers